Fein Seymour Howard's Form 4 filing
Oncotelic Therapeutics, Inc. (OTLC) · filed Jul 23, 2026
- Accession no.
- 0001493152-26-034397
- Filed
- Jul 23, 2026, 4:00 PM ET
- Trade date
- Jul 10, 2026
- Filing delay
- 13 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 1 derivative transaction. It was filed 13 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fein Seymour HowardCIK 0002147180 | Officer (CRO/CMO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Series A Preferred Stock | AGrant or awardAcquired | +250 | $0.00 | $0 | 250 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.